Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...

U.S. President Donald Trump’s threats to impose tariffs on medicines could rattle an industry that has become a cornerstone ...

Request Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart @ Competitive Landscape Analysis: Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching US$8.85 billion in 2024 and an impressive US$36.55 billion by 2032. Market ...

In the United States, Gazyva is part of a collaboration between Genentech and Biogen. REGENCY [NCT04221477] is a phase ...

Technology is changing how physicians think about assessing patients and, in turn, how patients expect to be able to measure their own health. Apps designed for smartphones and wearable devices can ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase ...

Switzerland) and the University of Rochester School of Medicine and Dentistry. The study was sponsored by Biogen in ...